Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va., June 05, 2024 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the first patient has been dosed in a pharmacokineti ...

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City. Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m ...

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City. Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m. ...

GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "We are making steady progress as it relates to AD04. We have initiated new a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38323 ADIAL PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3074668 State ...

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial's intellectual property protection and covers the combination of the Company's proprietary genetic diagno ...

Follow Invezz on Telegram , Twitter , and Google News for instant updates >Adial Pharmaceuticals Inc (NASDAQ: ADIL) is up 60% today following a promising update on its alcohol disorder drug.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.What it means for Adial Pharmaceuticals stock Copy link to section The $7.7 million company based out of Virginia, United States said its AD04 did well in a clinical trial of Alcohol Use Disorder (AUD) patients. Its l ...

Group 1 - Adial Pharmaceuticals' stock is experiencing a significant increase following positive peer-reviewed results for its Alcohol Use Disorder (AUD) treatment, AD04 [1] - The peer review published in the European Journal of Internal Medicine emphasizes the treatment's efficacy and safety, particularly for patients with a specific genetic background [1] - CEO Cary Claiborne highlighted the potential of AD04 to enable precision treatments for AUD, aiming to manage alcohol consumption and reduce liver damage [1] Group 2 - Heavy trading activity was noted, with over 75 million shares of ADIL stock changing hands, significantly surpassing the average daily trading volume of approximately 4 million shares [2] - As of Wednesday morning, ADIL stock rose by 59.3%, recovering its year-to-date losses [2]

GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD04 (low-dose ondansetron), the Company's lead investigational new drug produ ...

Core Insights - Adial Pharmaceuticals has made significant progress in 2023 towards the potential approval and commercial launch of its lead investigational drug AD04 for treating Alcohol Use Disorder, receiving favorable feedback from US and EU regulators [2][3] - The company is in discussions with potential strategic partners to support the development and launch of AD04, which is expected to enhance resource availability and market penetration post-approval [2] - Adial's financial position remains strong, with cash and cash equivalents of $2.8 million as of December 31, 2023, and an additional $4.3 million received from warrant exercises, allowing for continued development into 2025 [8] Business Developments - The appointment of Tony Goodman as Chief Operating Officer is aimed at overseeing strategic growth initiatives, including clinical development and commercial planning for AD04 [3] - Adial has received key patents from the USPTO for its proprietary genetic diagnostic technology, which is designed to identify patients for targeted treatment of Alcohol Use Disorder and opioid use disorder [4][5] - The company was recognized with the 2023 Best Practices Technology Innovation Leadership Award by Frost & Sullivan for its contributions to precision medicine in addiction disorders [5][6] Financial Performance - Research and development expenses decreased by approximately $683 thousand (35%) in 2023 compared to 2022, primarily due to reduced clinical and statistical consulting costs [8] - General and administrative expenses also saw a reduction of about $3.3 million (37%) in 2023, largely due to decreased equity-based compensation and salary costs [8] - The net loss for the year ended December 31, 2023, was $5.1 million, a significant improvement from a net loss of $12.7 million in 2022 [8]